BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35263037)

  • 21. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
    Kim G; Kim M; Nam EJ; Lee JY; Park E
    Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.
    Improgo MR; Schlichting NA; Cortes RY; Zhao-Shea R; Tapper AR; Gardner PD
    Mol Cancer Res; 2010 Feb; 8(2):194-203. PubMed ID: 20124469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
    Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
    Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
    Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
    Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
    Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
    Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
    Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
    Donakonda S; Sinha S; Dighe SN; Rao MRS
    Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
    Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
    Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
    Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
    Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
    Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lurbinectedin in the treatment of relapsed small cell lung cancer.
    Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
    Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Alam SK; Wang L; Ren Y; Hernandez CE; Kosari F; Roden AC; Yang R; Hoeppner LH
    Br J Cancer; 2020 Sep; 123(5):819-832. PubMed ID: 32499571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
    Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
    J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
    Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
    World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.
    Kim JH; Lee SY; Choi JE; Do SK; Lee JH; Hong MJ; Kang HG; Lee WK; Shin KM; Jeong JY; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2020 Jan; 11(1):19-28. PubMed ID: 31691490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.